Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

Muthiah Vaduganathan, MD, MPH, offers perspective on data from the PARAGLIDE-HF trial as well as a pooled analysis of data from the PARAGLIDE-HF and PARAGON-HF trials.

There is no additional risk of developing new cancers for patients treated with IBD medications.

According to a release from Oculis, the trial met its stage 1 objective of validating the dosing regimen designed to optimize the efficacy potential of OCS-01 with statistical significance.

The US Food and Drug Administration (FDA) has approved the adalimumab-adbm (Cyltezo) autoinjector pen ahead of the July 1 commercial launch.

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

Friedman spoke in this interview segment on improvements that have been made and improvements that he believes are needed to affect change regarding atopic dermatitis treatment disparities.

Statistically significant improvements were observed in all 10 PROMIS domains analyzed.

An analysis of the COPDGene Study presented at ATS 2023 suggests presence of mucus plugs in medium- to large-sized airways were associated with an increased risk of mortality in adjusted models.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

An analysis of patient-reported outcomes data from more than 15,000 people with rheumatic disease sheds light on the apparent differences in impact on quality of life between psoriatic arthritis and rheumatoid arthritis.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

However, trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

During this interview segment, Friedman further explored the topics in his presentation on fixing disparities in care for eczema patients through teledermatology.

Dermatology experts review available treatment options for the treatment of rare dermatological disorders.

Experts discuss challenges in managing rare dermatological disorders.

Ophthalmologist experts provide an overview of emerging treatments for dry eye disease.

Ophthalmologist experts discuss treating patients with dry eye disease who wear contacts.

The June 22, 2023 PDUFA date for obeticholic acid 25 mg oral tablets for the treatment of precirrhotic liver fibrosis appears to be in jeopardy after a May 23, 2023 meeting of the FDA's Gastrointestinal Drugs Advisory Committee.

The analyses emphasized the early and sustained resolution of enthesitis through 52 weeks with both adalimumab and secukinumab.

The structure of the retinal vasculature may be able to predict the initial treatment response to intravitreal therapy in patients with treatment-naïve nAMD.

The study revealed that healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before their third COVID-19 vaccination, but this effect was mediated by age and body mass index.

A fibromyalgia diagnosis was significantly associated with GERD, IBS, Crohn’s disease, ulcerative colitis, and celiac disease.

Paul Ruberg, PA-C, presents a patient case and discusses the importance of educating patients and about the treatment process.

Merrideth Leggat, MD, reviews clinical and practical implications of findings from the TRANSFORM and SUSTAIN studies exploring the utility of esketamine in the treatment of TRD.